Wird geladen...
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Immunotherapy with programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) targeted monoclonal antibodies has dramatically changed the therapeutic and prognostic landscape for several types of malignancy. PD-1 and PD-L1 are immune checkpoint proteins whose binding ultimately result in T cell...
Gespeichert in:
| Veröffentlicht in: | Mol Diagn Ther |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5773410/ https://ncbi.nlm.nih.gov/pubmed/29119407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40291-017-0308-6 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|